Journal Information
Vol. 33. Issue 3.
Pages 125-133 (January 2009)
Vol. 33. Issue 3.
Pages 125-133 (January 2009)
Full text access
Pharmacokinetics and pharmacodynamics of the new oral anticoagulants
Farmacocinética y farmacodinamia de los nuevos anticoagulantes orales
Visits
4444
Juan Pablo Ordovás Bainesa,b,
Corresponding author
ordovas_jua@gva.es

Corresponding author.
, Eduardo Climent Granaa,b, Alejandro Jover Botellaa, Isabel Valero Garcíaa
a Servicio de Farmacia, Hospital General Universitario de Alicante, Alicante, Spain
b Facultad de Farmacia, Universidad Miguel Hernández, Elche, Alicante, Spain
This item has received
Article information
Abstract

Dabigatran is the first available oral direct thrombin inhibitor anticoagulant. Absorption of the prodrug, dabigatran etexilate and its conversion to dabigatran is rapid (peak plasma concentrations are reached 4–6h following surgery, and a further 2h later). Its oral bioavailability is low, but shows reduced interindividual variability. Dabigatran specifically and reversibly inhibits thrombin, the key enzyme in the coagulation cascade. Studies both in healthy volunteers and in patients undergoing major orthopaedic surgery show a predictable pk/pd profile that allows for fixed-dose regimens. The anticoagulant effect correlates adequately with the plasma concentrations of the drug, demonstrating effective anticoagulation combined with a low risk of bleeding. Dabigatran is mainly eliminated by renal excretion (a fact which affects the dosage in elderly and in moderate-severe renal failure patients), and no hepatic metabolism by cytochrome P450 isoenzymes has been observed, showing a good interaction profile.

Rivaroxaban will probably be the first available oral factor Xa (FXa) direct inhibitor anticoagulant drug. It produces a reversible and predictable inhibition of FXa activity with potential to inhibit clot-bound FXa. Its pharmacokinetic characteristics include rapid absorption, high oral availability, high plasma protein binding and a half-life of aprox. 8h. Rivaroxaban elimination is mainly renal, but also through faecal matter and by hepatic metabolism. Although the drug has demonstrated moderate potential to interact with strong CYP3A4 inhibitors, it does not inhibit or induce any major CYP450 enzyme.

Keywords:
Anticoagulants
Direct thrombin inhibitors
Direct factor Xa inhibitors
Pharmacokinetics
Pharmacodynamics
Resumen

Dabigatran es el primer anticoagulante inhibidor directo de la trombina disponible por vía oral. La absorción del profármaco dabigatran etexilato y su conversión a dabigatran es rápida (concentraciones máximas de 4–6h tras cirugía y 2h posteriormente) y, pese a la baja biodisponibilidad oral, presenta escasa variabilidad entre individuos. Inhibe específica y reversiblemente la trombina, la enzima llave de la cascada de la coagulación. Los estudios tanto en voluntarios sanos como en pacientes sometidos a cirugía ortopédica mayor muestran un perfil pk/pd predecible, lo que permite regímenes fijos de dosificación. El efecto anticoagulante se correlaciona bien con las concentraciones plasmáticas del fármaco, lo que aúna una efectiva anticoagulación con un bajo riesgo de hemorragia. La excreción es mayoritariamente renal (lo que condiciona su dosificación en pacientes ancianos y con insuficiencia renal), y no sufre metabolismo hepático por el sistema del citocromo P450, por lo que presenta un perfil de fármaco sin grandes problemas de interacción con otros medicamentos.

Rivaroxaban será probablemente el primer fármaco anticoagulante oral inhibidor directo del factor Xa (FXa) disponible. Produce una inhibición reversible y predecible de la actividad del FXa con capacidad de inhibir el FXa ligado al coágulo. Sus características farmacocinéticas incluyen rápida absorción, con elevadas biodisponibilidad y unión a proteínas plasmáticas y semivida de eliminación de, aproximadamente, 8 h. La eliminación es de tipo dual, renal (mayoritaria) y biliar. Aunque ha demostrado tener un potencial moderado de interacción con inhibidores fuertes del citocromo P450-A4, no parece inhibir ni inducir ninguna enzima P450.

Palabras clave:
Anticoagulantes
Inhibidores directos de la trombina
Inhibidores directos del factor Xa
Farmacocinética
Farmacodinamia
Full text is only available in PDF
References
[1.]
J.I. Weitz.
New anticoagulants for treatment of venous thromboembolism.
Circulation, 110 (2004), pp. I19-I26
[2.]
L.A. Linkins, J.I. Weitz.
New anticoagulant therapy.
[3.]
J. Hirsh, M. O’Donnell, J.I. Weitz.
New Anticoagulants.
Blood, 105 (2005), pp. 453-463
[4.]
A.D. Blann, G.Y.H. Lip.
Venous thromboembolism.
[5.]
J.S. McRae, J.W. Eikelboom.
Latest medical treatment strategies for venous thromboembolism.
Expert Opin Pharmacother, 8 (2007), pp. 1221-1233
[6.]
D. Warwick, R.J. Friedman, G. Agnelli, (From the Global Orthopaedic Registry), et al.
Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events.
J Bone Joint Surg Br, 89-B (2007), pp. 799-807
[7.]
S.M. Bates, J.I. Weitz.
New anticoagulants beyond heparin, low-molecular-weight heparin and warfarin.
Br J Pharmacol, 144 (2005), pp. 1017-1028
[8.]
K. Bauer.
New anticoagulants.
Hematology Am Soc Hematol Educ Program, 1 (2006), pp. 450-456
[9.]
J.I. Weitz, J. Hirsh, M.M. Samama.
New antithrombotic drugs (American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th Edition).
Chest, 133 (2008), pp. 234-256
[10.]
S.S. Desai, M.G. Massad, R.J. DiDomenico, K. Abdelhady, Z. Hanhan, H. Lele, et al.
Recent developments in antithrombotic therapy: will sodium warfarin be a drug of the past?.
Recent Pat Cardiovasc Drug Discov, 1 (2006), pp. 307-316
[11.]
J.I. Weitz, L.A. Linkins.
Beyond heparin and warfarin: the new generation of anticoagulants.
Expert Opin Investig Drugs, 16 (2007), pp. 271-282
[12.]
N.H. Hauel, H. Nar, H. Priepke, U. Ries, J.M. Stassen, W. Wienen.
Structure-based design of novel potent nonpeptide thrombin inhibitors.
J Med Chem, 45 (2002), pp. 1757-1766
[13.]
T. Steinmetzer, J. Hauptmann, J. Sturzebecher.
Advances in the development of thrombin inhibitors.
Expert Opin Investig Drugs, 10 (2001), pp. 845-864
[14.]
D.J. Pinto, M.J. Orwat, S. Koch, K.A. Rossi, R.S. Alexander, A. Smallwood, et al.
Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4, 5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridine- 3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
J Med Chem, 50 (2007), pp. 5339-5356
[15.]
S. Roehrig, A. Straub, J. Pohlmann, T. Lampe, J. Pernerstorfer, K.H. Schlemmer, et al.
Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl] -1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.
J Med Chem, 48 (2005), pp. 5900-5908
[16.]
E. Perzborn, J. Strassburger, A. Wilmen, J. Pohlmann, S. Roehrig, K.H. Schlemmer, et al.
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 — An oral, direct factor Xa inhi bitor.
J Thromb Haemost, 3 (2005), pp. 514-521
[17.]
M.R. Lassen, B.L. Davidson, A. Gallus, G. Pineo, J. Ansell, D. Deitchman.
The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
J Thromb Haemost, 5 (2007), pp. 2368-2375
[18.]
European Medicines Agency (EMEA). Pradaxa H-C-829. European Public Assessment Report. Revision 2. 2009 [cited, Mar 17, 2009]. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/pradaxa/H-829-en6.pdf
[19.]
J. Stangier.
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
Clin Pharmacokinet, 47 (2008), pp. 285-295
[20.]
European Medicines Agency (EMEA). Xarelto H-C-944. European Public Assessment Report. Revision 1. 2009 [cited, Mar 19, 2009]. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/xarelto/H-944-en6.pdf
[21.]
K.G. Mann, K. Brummel, S. Butenas.
What is all that thrombin for?.
J Thromb Haemost, 1 (2003), pp. 1504-1514
[22.]
K.G. Mann, S. Butenas, K. Brummel.
The dynamics of thrombin formation.
Arterioscler Thromb Vasc Biol, 23 (2003), pp. 17-25
[23.]
M.P. Gulseth, J. Michaud, E.A. Nutescu.
Rivaroxaban: an oral direct inhibitor of factor Xa.
Am J Health Syst Pharm, 65 (2008), pp. 1520-1529
[24.]
J.I. Weitz.
Factor Xa or thrombin: is thrombin a better target?.
J Thromb Haemost, 5 (2007), pp. 65-67
[25.]
N.M. Di, S. Middeldorp, H.R. Buller.
Direct thrombin inhibitors.
N Engl J Med, 353 (2005), pp. 1028-1040
[26.]
G.T. Gerotziafas, I. Elalamy, F. Depasse, E. Perzborn, M.M. Samama.
In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban.
J Thromb Haemost, 5 (2007), pp. 886-888
[27.]
J. Graff, H.N. Von, F. Misselwitz, D. Kubitza, M. Becka, H.K. Breddin, et al.
Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.
J Clin Pharmacol, 47 (2007), pp. 1398-1407
[28.]
W. Wienen, J.M. Stassen, H. Priepke, U.J. Ries, N. Hauel.
In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
Thromb Haemost, 98 (2007), pp. 155-162
[29.]
W. Wienen, J.M. Stassen, H. Priepke, U.J. Ries, N. Hauel.
Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis.
J Thromb Haemost, 5 (2007), pp. 1237-1242
[30.]
D. Kubitza, M. Becka, B. Voith, M. Zuehlsdorf, G. Wensing.
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
Clin Pharmacol Ther, 78 (2005), pp. 412-421
[31.]
J. Stangier, B.I. Eriksson, O.E. Dahl, L. Ahnfelt, G. Nehmiz, H. Stahle, et al.
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.
J Clin Pharmacol, 45 (2005), pp. 555-563
[32.]
B.I. Eriksson, O.E. Dahl, L. Ahnfelt, P. Kalebo, J. Stangier, G. Nehmiz, et al.
Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
J Thromb Haemost, 2 (2004), pp. 1573-1580
[33.]
G. Nowak.
The ecarin clotting time, a universal method to quantify direct thrombin inhibitors.
Pathophysiol Haemost Thromb, 33 (2003), pp. 173-183
[34.]
D. Kubitza, M. Becka, M. Zuehlsdorf, W. Mueck.
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.
J Clin Pharmacol, 47 (2007), pp. 218-226
[35.]
W. Mueck, B.I. Eriksson, K.A. Bauer, L. Borris, O.E. Dahl, W.D. Fisher, et al.
Population pharmacokinetics and pharmacodynamics of rivaroxaban — an oral, direct factor Xa inhibitor — in patients undergoing major orthopaedic surgery.
Clin Pharmacokinet, 47 (2008), pp. 203-216
[36.]
D. Kubitza, M. Becka, M. Zuehlsdorf, W. Mueck.
Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.
J Clin Pharmacol, 46 (2006), pp. 549-558
[37.]
S. Blech, T. Ebner, E. Ludwig-Schwellinger, J. Stangier, W. Roth.
The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.
Drug Metab Dispos, 36 (2008), pp. 386-399
[38.]
I.F. Trocóniz, C. Tillmann, K.H. Liesenfeld, H.G. Schäfer, J. Stangier.
Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery.
J Clin Pharmacol, 47 (2007), pp. 371-382
[39.]
J. Stangier, K. Rathgen, H. Stähle, D. Gansser, W. Roth.
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Br J Clin Pharmacol, 64 (2007), pp. 292-303
[40.]
A. Halabi, H. Maatouk, N. Klause, et al.
Effects of renal impairment on the pharmacology of rivaroxaban (BAY 59-7939), an oral, direct factor Xa inhibitor.
Blood, (2006), pp. 108
[41.]
G. Escolar, J. Villalta, F. Casals, J. Bozzo, N. Serradell, J. Bolós.
Rivaroxaban (Bay-59-7939).
Drugs Fut, 31 (2006), pp. 484-493
[42.]
D. Kubitza, M. Becka, W. Mueck, M. Zuehlsdorf.
Rivaroxaban (BAY 59-7939) — an oral, direct Factor Xa inhibitor — has no clinically relevant interaction with naproxen.
Br J Clin Pharmacol, 63 (2007), pp. 469-476
[43.]
D. Kubitza, M. Becka, W. Mueck, M. Zuehlsdorf.
Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban—an oral, direct factor Xa inhibitor—are not affected by aspirin.
J Clin Pharmacol, 46 (2006), pp. 981-990
Copyright © 2009. Sociedad Española de Farmacia Hospitalaria
Download PDF
Idiomas
Farmacia Hospitalaria
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.